{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:57:58Z","timestamp":1791849478718,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Tumor-related eosinophilia may have extended survival benefits for some cancer patients. However, there has been no report on the prognosis difference between eosinophilic pleural effusion (EPE) and non-EPE in lung cancer patients. Our study aimed to investigate the prognosis difference between EPE and non-EPE due to lung cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed patients diagnosed with lung cancer who presented with malignant pleural effusion (MPE) between May 2007 and September 2020 at the National Hospital Organization Kochi Hospital. EPE is defined as pleural fluid with a nucleated cell count containing 10% or more eosinophils.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 152 patients were included: 89 were male (59%). The median age was 74.4\u00a0years (range 37\u2013101), and all patients were pathologically shown to have MPE. Most patients (140; 92%) had an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0\/1. Twenty patients had EPE. The median overall survival (OS) of all 152 lung cancer patients with MPE was 298\u00a0days. The median OS of the patients with EPE was 766\u00a0days, and the median OS of the patients with non-EPE was 252\u00a0days. Kaplan\u2013Meier univariate analysis showed that lung cancer patients with EPE had a significantly better prognosis than patients with non-EPE (P\u2009&lt;\u20090.05). Cox proportional regression analysis showed that EPE, ECOG PS, sex, and the neutrophil-to-lymphocyte ratio in the serum (sNLR) may be independent prognostic factors affecting survival in patients with MPE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Lung cancer patients with EPE have a better prognosis than those with non-EPE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00262-021-02994-5","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T11:03:16Z","timestamp":1624618996000},"page":"365-372","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Eosinophilic pleural effusion due to lung cancer has a better prognosis than non-eosinophilic malignant pleural effusion"],"prefix":"10.1007","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1541-9747","authenticated-orcid":false,"given":"Eiji","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Okano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanori","family":"Machida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiro","family":"Atagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kondou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kadota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishi","family":"Naruse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"key":"2994_CR1","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1378\/chest.110.5.1271","volume":"110","author":"JB Rubins","year":"1996","unstructured":"Rubins JB, Rubins HB (1996) Etiology and prognostic significance of eosinophilic pleural effusions. Prospect Study Chest 110:1271\u20131274. https:\/\/doi.org\/10.1378\/chest.110.5.1271","journal-title":"Prospect Study Chest"},{"key":"2994_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000327200","volume":"83","author":"Y Oba","year":"2012","unstructured":"Oba Y, Abu-Salah T (2012) The prevalence and diagnostic significance of eosinophilic pleural effusions: a meta-analysis and systematic review. Respiration 83:198\u2013208. https:\/\/doi.org\/10.1159\/000327200","journal-title":"Respiration"},{"key":"2994_CR3","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00262-012-1288-3","volume":"61","author":"S Gatault","year":"2012","unstructured":"Gatault S, Legrand F, Delbeke M, Loiseau S, Capron M (2012) Involvement of eosinophils in the anti-tumor response. Cancer Immunol Immunother 61:1527\u20131534. https:\/\/doi.org\/10.1007\/s00262-012-1288-3","journal-title":"Cancer Immunol Immunother"},{"key":"2994_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1158\/2326-6066.CIR-13-0196","volume":"2","author":"BP Davis","year":"2014","unstructured":"Davis BP, Rothenberg ME (2014) Eosinophils and cancer. Cancer. Immunol Res 2:1\u20138. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0196","journal-title":"Immunol Res"},{"key":"2994_CR5","doi-asserted-by":"publisher","first-page":"e1393134","DOI":"10.1080\/2162402X.2017.1393134","volume":"7","author":"G Varricchi","year":"2018","unstructured":"Varricchi G, Galdiero MR, Loffredo S, Lucarini V, Marone G, Mattei F, Marone G, Schiavoni G (2018) Eosinophils: The unsung heroes in cancer? Oncoimmunology 7:e1393134. https:\/\/doi.org\/10.1080\/2162402X.2017.1393134","journal-title":"Oncoimmunology"},{"key":"2994_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","volume":"82","author":"MV Heppt","year":"2017","unstructured":"Heppt MV, Heinzerling L, K\u00e4hler KC et al (2017) Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1\/cytotoxic T-lymphocyte antigen-4 inhibition. Eur J Cancer 82:56\u201365. https:\/\/doi.org\/10.1016\/j.ejca.2017.05.038","journal-title":"Eur J Cancer"},{"key":"2994_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.2217\/imt-2016-0138","volume":"9","author":"A Moreira","year":"2017","unstructured":"Moreira A, Leisgang W, Schuler G, Heinzerling L (2017) Eosinophilic count as a biomarker for prognosis of melanoma patients and its importance in the response to immunotherapy. Immunotherapy 9:115\u2013121. https:\/\/doi.org\/10.2217\/imt-2016-0138","journal-title":"Immunotherapy"},{"key":"2994_CR8","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","volume":"21","author":"C Gebhardt","year":"2015","unstructured":"Gebhardt C, Sevko A, Jiang H et al (2015) Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab. Clin Cancer Res 21:5453\u20135459. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0676","journal-title":"Clin Cancer Res"},{"key":"2994_CR9","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide B, Martens A, Hassel JC et al (2016) Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin Cancer Res 22:5487\u20135496. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0127","journal-title":"Clin Cancer Res"},{"key":"2994_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jtho.2017.10.030","volume":"13","author":"J Tanizaki","year":"2018","unstructured":"Tanizaki J, Haratani K, Hayashi H et al (2018) Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. J Thorac Oncol 13:97\u2013105. https:\/\/doi.org\/10.1016\/j.jtho.2017.10.030","journal-title":"J Thorac Oncol"},{"key":"2994_CR11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2020.08.015","volume":"150","author":"X Chu","year":"2020","unstructured":"Chu X, Zhao J, Zhou J et al (2020) Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Lung Cancer 150:76\u201382. https:\/\/doi.org\/10.1016\/j.lungcan.2020.08.015","journal-title":"Lung Cancer"},{"key":"2994_CR12","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/thx.34.1.106","volume":"34","author":"A Hirsch","year":"1979","unstructured":"Hirsch A, Ruffie P, Nebut M, Bignon J, Chretien J (1979) Pleural effusion: laboratory tests in 300 cases. Thorax 34:106\u2013112. https:\/\/doi.org\/10.1136\/thx.34.1.106","journal-title":"Thorax"},{"key":"2994_CR13","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1001\/archinte.1973.03650120060011","volume":"132","author":"RW Light","year":"1973","unstructured":"Light RW, Erozan YS, Ball WC Jr (1973) Cells in pleural fluid. Their value in differential diagnosis. Arch Intern Med 132:854\u2013860","journal-title":"Arch Intern Med"},{"key":"2994_CR14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/0002-9343(84)90542-4","volume":"77","author":"M Adelman","year":"1984","unstructured":"Adelman M, Albelda SM, Gottlieb J, Haponik EF (1984) Diagnostic utility of pleural fluid eosinophilia. Am J Med 77:915\u2013920. https:\/\/doi.org\/10.1016\/0002-9343(84)90542-4","journal-title":"Am J Med"},{"key":"2994_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1183\/09031936.00197708","volume":"34","author":"R Krenke","year":"2009","unstructured":"Krenke R, Nasilowski J, Korczynski P, Gorska K, Przybylowski T, Chazan R, Light RW (2009) Incidence and aetiology of eosinophilic pleural effusion. Eur Respir J 34:1111\u20131117. https:\/\/doi.org\/10.1183\/09031936.00197708","journal-title":"Eur Respir J"},{"key":"2994_CR16","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1136\/thoraxjnl-2014-205285","volume":"69","author":"AO Clive","year":"2014","unstructured":"Clive AO, Kahan BC, Hooper CE et al (2014) Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax 69:1098\u20131104. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-205285","journal-title":"Thorax"},{"key":"2994_CR17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000356764","volume":"87","author":"S Anevlavis","year":"2014","unstructured":"Anevlavis S, Kouliatsis G, Sotiriou I, Koukourakis MI, Archontogeorgis K, Karpathiou G, Giatromanolaki A, Froudarakis ME (2014) Prognostic factors in patients presenting with pleural effusion revealing malignancy. Respiration 87:311\u2013316. https:\/\/doi.org\/10.1159\/000356764","journal-title":"Respiration"},{"key":"2994_CR18","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12890-015-0025-z","volume":"15","author":"MM Zamboni","year":"2015","unstructured":"Zamboni MM, Silva de CT, Baretta jr R, Cunha ET, Cardoso GP (2015) Important prognostic factors for survival in patients with malignant pleural effusion. BMC Pulm Med 15:29. https:\/\/doi.org\/10.1186\/s12890-015-0025-z","journal-title":"BMC Pulm Med"},{"key":"2994_CR19","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12885-017-3550-8","volume":"17","author":"YS Lee","year":"2017","unstructured":"Lee YS, Nam HS, Lim JH, Kim JS, Moon Y, Cho JH, Ryu JS, Kwak SM, Lee HL (2017) Prognostic impact of a new score using neutrophil-to-lymphocyte ratios in the serum and malignant pleural effusion in lung cancer patients. BMC Cancer 17:557. https:\/\/doi.org\/10.1186\/s12885-017-3550-8","journal-title":"BMC Cancer"},{"key":"2994_CR20","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/s0385-8146(01)00135-3","volume":"29","author":"M Fujii","year":"2002","unstructured":"Fujii M, Yamashita T, Ishiguro R, Tashiro M, Kameyama K (2002) Significance of epidermal growth factor receptor and tumor associated tissue eosinophilia in the prognosis of patients with nasopharyngeal carcinoma. Auris Nasus Larynx 29:175\u2013181. https:\/\/doi.org\/10.1016\/s0385-8146(01)00135-3","journal-title":"Auris Nasus Larynx"},{"key":"2994_CR21","first-page":"1419","volume":"26","author":"S Ishibashi","year":"2006","unstructured":"Ishibashi S, Ohashi Y, Suzuki T, Miyazaki S, Moriya T, Satomi S, Sasano H (2006) Tumor-associated tissue eosinophilia in human esophageal squamous cell carcinoma. Anticancer Res 26:1419\u20131424","journal-title":"Anticancer Res"},{"key":"2994_CR22","first-page":"2997","volume":"43","author":"TP Pretlow","year":"1983","unstructured":"Pretlow TP, Keith EF, Cryar AK, Bartolucci AA, Pitts AM, Pretlow TG 2nd, Kimball PM, Boohaker EA (1983) Eosinophil infiltration of human colonic carcinomas as a prognostic indicator. Cancer Res 43:2997\u20133000","journal-title":"Cancer Res"},{"key":"2994_CR23","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/(SICI)1097-0142(20000401)88:7<1544::AID-CNCR7>3.0.CO;2-S","volume":"88","author":"MJ Fern\u00e1ndez-Ace\u00f1ero","year":"2000","unstructured":"Fern\u00e1ndez-Ace\u00f1ero MJ, Galindo-Gallego M, Sanz J, Aljama A (2000) Prognostic influence of tumor-associated eosinophilic infiltrate in colorectal carcinoma. Cancer 88:1544\u20131548","journal-title":"Cancer"},{"key":"2994_CR24","first-page":"2391","volume":"22","author":"I Takanami","year":"2002","unstructured":"Takanami I, Takeuchi K, Gika M (2002) Immunohistochemical detection of eosinophilic infiltration in pulmonary adenocarcinoma. Anticancer Res 22:2391\u20132396","journal-title":"Anticancer Res"},{"key":"2994_CR25","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.revmed.2005.02.013","volume":"26","author":"R Costello","year":"2005","unstructured":"Costello R, O\u2019Callaghan T, S\u00e9bahoun G (2005) Eosinophils and antitumour response. Rev Med Interne 26:479\u2013484. https:\/\/doi.org\/10.1016\/j.revmed.2005.02.013","journal-title":"Rev Med Interne"},{"key":"2994_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/s0344-0338(97)80006-4","volume":"193","author":"S Luna-Mor\u00e9","year":"1997","unstructured":"Luna-Mor\u00e9 S, Florez P, Ayala A, Diaz F, Santos A (1997) Neutral and acid mucins and eosinophil and argyrophil crystalloids in carcinoma and atypical adenomatous hyperplasia of the prostate. Pathol Res Pract 193:291\u2013298. https:\/\/doi.org\/10.1016\/s0344-0338(97)80006-4","journal-title":"Pathol Res Pract"},{"key":"2994_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1046\/j.1442-2042.2002.00424.x","volume":"9","author":"Y Ono","year":"2002","unstructured":"Ono Y, Ozawa M, Tamura Y, Suzuki T, Suzuki K, Kurokawa K, Fukabori Y, Yamanaka H (2002) Tumor-associated tissue eosinophilia of penile cancer. Int J Urol 9:82\u201387. https:\/\/doi.org\/10.1046\/j.1442-2042.2002.00424.x","journal-title":"Int J Urol"},{"key":"2994_CR28","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1182\/blood.V95.4.1207.004k34_1207_1213","volume":"95","author":"R von Wasielewski","year":"2000","unstructured":"von Wasielewski R, Seth S, Franklin J, Fischer R, H\u00fcbner K, Hansmann ML, Diehl V, Georgii A (2000) Tissue eosinophilia correlates strongly with poor prognosis in nodular sclerosing Hodgkin\u2019s disease, allowing for known prognostic factors. Blood 95:1207\u20131213","journal-title":"Blood"},{"key":"2994_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.14670\/hh-29.387","volume":"29","author":"JM da Silva","year":"2014","unstructured":"da Silva JM, Queiroz-Junior CM, Batista AC, Rachid MA, Teixeira MM, Silva da TA (2014) Eosinophil depletion protects mice from tongue squamous cell carcinoma induced by 4-nitroquinoline-1-oxide. Histol Histopathol 29:387\u2013396. https:\/\/doi.org\/10.14670\/hh-29.387","journal-title":"Histol Histopathol"},{"key":"2994_CR30","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.trecan.2016.10.002","volume":"2","author":"H Reichman","year":"2016","unstructured":"Reichman H, Karo-Atar D, Munitz A (2016) Emerging roles for eosinophils in the tumor microenvironment. Trends Cancer 2:664\u2013675. https:\/\/doi.org\/10.1016\/j.trecan.2016.10.002","journal-title":"Trends Cancer"},{"key":"2994_CR31","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s00262-018-2255-4","volume":"68","author":"SCS Simon","year":"2019","unstructured":"Simon SCS, Utikal J, Umansky V (2019) Opposing roles of eosinophils in cancer. Cancer Immunol Immunother 68:823\u2013833. https:\/\/doi.org\/10.1007\/s00262-018-2255-4","journal-title":"Cancer Immunol Immunother"},{"key":"2994_CR32","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41568-020-0283-9","volume":"20","author":"S Grisaru-Tal","year":"2020","unstructured":"Grisaru-Tal S, Itan M, Klion AD, Munitz A (2020) A new dawn for eosinophils in the tumour microenvironment. Nat Rev Cancer 20:594\u2013607. https:\/\/doi.org\/10.1038\/s41568-020-0283-9","journal-title":"Nat Rev Cancer"},{"key":"2994_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/bf01629431","volume":"118","author":"E Huland","year":"1992","unstructured":"Huland E, Huland H (1992) Tumor-associated eosinophilia in interleukin-2-treated patients: evidence of toxic eosinophil degranulation on bladder cancer cells. J Cancer Res Clin Oncol 118:463\u2013467. https:\/\/doi.org\/10.1007\/bf01629431","journal-title":"J Cancer Res Clin Oncol"},{"key":"2994_CR34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1002\/eji.200323727","volume":"33","author":"HU Simon","year":"2003","unstructured":"Simon HU, Pl\u00f6tz S, Simon D, Seitzer U, Braathen LR, Menz G, Straumann A, Dummer R, Levi-Schaffer F (2003) Interleukin-2 primes eosinophil degranulation in hypereosinophilia and wells\u2019 syndrome. Eur J Immunol 33:834\u2013839. https:\/\/doi.org\/10.1002\/eji.200323727","journal-title":"Eur J Immunol"},{"key":"2994_CR35","first-page":"805","volume":"1","author":"JA Sosman","year":"1995","unstructured":"Sosman JA, Bartemes K, Offord KP et al (1995) Evidence for eosinophil activation in cancer patients receiving recombinant interleukin-4: effects of interleukin-4 alone and following interleukin-2 administration. Clin Cancer Res 1:805\u2013812","journal-title":"Clin Cancer Res"},{"key":"2994_CR36","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/s1525-0016(03)00103-5","volume":"7","author":"JA Bristol","year":"2003","unstructured":"Bristol JA, Zhu M, Ji H, Mina M, Xie Y, Clarke L, Forry-Schaudies S, Ennist DL (2003) In vitro and in vivo activities of an oncolytic adenoviral vector designed to express GM-CSF. Mol Ther 7:755\u2013764. https:\/\/doi.org\/10.1016\/s1525-0016(03)00103-5","journal-title":"Mol Ther"},{"key":"2994_CR37","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1479-5876-8-79","volume":"8","author":"JT Schaefer","year":"2010","unstructured":"Schaefer JT, Patterson JW, Deacon DH, Smolkin ME, Petroni GR, Jackson EM, Slingluff CL Jr (2010) Dynamic changes in cellular infiltrates with repeated cutaneous vaccination: a histologic and immunophenotypic analysis. J Transl Med 8:79. https:\/\/doi.org\/10.1186\/1479-5876-8-79","journal-title":"J Transl Med"},{"key":"2994_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1165\/ajrcmb\/3.4.291","volume":"3","author":"Y Nakamura","year":"1990","unstructured":"Nakamura Y, Ozaki T, Yanagawa H, Yasuoka S, Ogura T (1990) Eosinophil colony-stimulating factor induced by administration of interleukin-2 into the pleural cavity of patients with malignant pleurisy. Am J Respir Cell Mol Biol 3:291\u2013300. https:\/\/doi.org\/10.1165\/ajrcmb\/3.4.291","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2994_CR39","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/ni.3159","volume":"16","author":"R Carretero","year":"2015","unstructured":"Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, H\u00e4mmerling GJ (2015) Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8(+) T cells. Nat Immunol 16:609\u2013617. https:\/\/doi.org\/10.1038\/ni.3159","journal-title":"Nat Immunol"},{"key":"2994_CR40","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1186\/s12885-018-4262-4","volume":"18","author":"M Salimi","year":"2018","unstructured":"Salimi M, Wang R, Yao X et al (2018) Activated innate lymphoid cell populations accumulate in human tumour tissues. BMC Cancer 18:341. https:\/\/doi.org\/10.1186\/s12885-018-4262-4","journal-title":"BMC Cancer"},{"key":"2994_CR41","doi-asserted-by":"publisher","first-page":"703","DOI":"10.4049\/jimmunol.1101270","volume":"188","author":"M Ikutani","year":"2012","unstructured":"Ikutani M, Yanagibashi T, Ogasawara M et al (2012) Identification of innate IL-5-producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol 188:703\u2013713. https:\/\/doi.org\/10.4049\/jimmunol.1101270","journal-title":"J Immunol"},{"key":"2994_CR42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-020-2015-4","volume":"579","author":"JA Moral","year":"2020","unstructured":"Moral JA, Leung J, Rojas LA et al (2020) ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. Nature 579:130\u2013135. https:\/\/doi.org\/10.1038\/s41586-020-2015-4","journal-title":"Nature"},{"key":"2994_CR43","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/00000441-200609000-00011","volume":"332","author":"J Heidecker","year":"2006","unstructured":"Heidecker J, Kaplan A, Sahn SA (2006) Pleural fluid and peripheral eosinophilia from hemothorax: hypothesis of the pathogenesis of EPE in hemothorax and pneumothorax. Am J Med Sci 332:148\u2013152. https:\/\/doi.org\/10.1097\/00000441-200609000-00011","journal-title":"Am J Med Sci"},{"key":"2994_CR44","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1164\/rccm.201302-0295OC","volume":"188","author":"BI Kwon","year":"2013","unstructured":"Kwon BI, Hong S, Shin K, Choi EH, Hwang JJ, Lee SH (2013) Innate type 2 immunity is associated with eosinophilic pleural effusion in primary spontaneous pneumothorax. Am J Respir Crit Care Med 188:577\u2013585. https:\/\/doi.org\/10.1164\/rccm.201302-0295OC","journal-title":"Am J Respir Crit Care Med"},{"key":"2994_CR45","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/ijc.32262","volume":"145","author":"N Tumino","year":"2019","unstructured":"Tumino N, Martini S, Munari E et al (2019) Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor. Int J Cancer 145:1660\u20131668. https:\/\/doi.org\/10.1002\/ijc.32262","journal-title":"Int J Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02994-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-021-02994-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-021-02994-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,22]],"date-time":"2022-01-22T07:05:10Z","timestamp":1642835110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-021-02994-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2994"],"URL":"https:\/\/doi.org\/10.1007\/s00262-021-02994-5","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"14 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest statement"}},{"value":"The institutional review board of the National Hospital Organization Kochi Hospital approved the study protocol (R2-13). Informed consent was waived because of the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}